One recent discrete choice survey of almost 300 cancer patients found that these patients chose G-CSF options with the lowest out-of-pocket expenses, the fewest injections, and lowest risk of disruption to chemotherapy schedule and infection requiring hospitalization most frequently [37]. This evidence concerns the gene CSF3 and cancer.